Wird geladen...
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
BACKGROUND: Immune checkpoint inhibitors have transformed the treatment landscape for many cancers, including metastatic melanoma, but have also opened the door for a diverse variety of immune-related adverse effects. CASE PRESENTATION: We describe the first reported case of presumed neurosarcoidosi...
Gespeichert in:
| Veröffentlicht in: | J Immunother Cancer |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6069826/ https://ncbi.nlm.nih.gov/pubmed/30064495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0390-2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|